The Phase 2 trial will investigate whether VT-122 in combination with Nexavar increases ‘Clinical Benefit Response,’ which is a composite measurement of pain, performance status, and lean body mass, as compared to Nexavar alone.
The secondary efficacy endpoints of this study are cancer and cachexia specific symptoms, duration of Nexavar therapy and overall survival.
The trail is expected to recruit around 80 patients with advanced liver cancer, systemic inflammation and cachexia at multiple sites in the US.